微生物组市场规模、份额和成长分析（按产品、应用和地区划分）－2026-2033年产业预测

预计到 2024 年，全球微生物组市场规模将达到 10.7225 亿美元，到 2025 年将增长至 12.6204 亿美元，到 2033 年将增长至 46.4819 亿美元，在预测期（2026-2033 年）内复合年增长率为 17.7%。

全球微生物组市场正经历显着成长，这主要得益于策略联盟的激增，这些联盟推动了微生物组治疗方法，进一步推动了市场的发展势头。此外，可透过微生物组干预治疗的疾病发生率不断上升，也促进了对这些治疗方法的需求成长。随着人们对微生物组在健康和疾病中关键作用的认识不断提高，具有影响力的治疗方法的潜力正在医疗保健领域创造一个充满活力且不断发展的环境，为相关人员提供了众多机会。

全球微生物组市场驱动因素

全球微生物组市场的发展动力源自于人类肠道微生物组在提升药物疗效方面所扮演的关键角色。研究表明，维持体内微生物群落的平衡有助于控制多种健康状况。微生物组与特定疾病之间的这种关联为药物研发和疫苗研发提供了创新机会。此外，这些微生物产生的丰富酶类表明其具有多种治疗应用潜力，为发现新型治疗方法开闢了新途径，并凸显了微生物组在推进医疗保健解决方案方面的重要性。

限制全球微生物组市场的因素

由于益生菌监管方面的挑战，全球微生物组市场面临许多製约。虽然益生菌尚未获得美国食品药物管理局 (FDA)核准作为活体生物治疗产品，但它们可以合法地作为食品和膳食补充剂销售。这个法规结构限制了声称具有治疗、缓解或预防疾病功效的产品的销售，并限制了其推广。因此，这种限制可能会阻碍市场成长和消费者认知度，因为企业在遵守严格的广告准则的同时，可能难以有效传达益生菌的潜在益处。这种监管不确定性最终可能会影响微生物组领域的投资和创新。

全球微生物组市场趋势

全球微生物组市场正呈现公私部门合作日益密切的显着趋势。这一成长势头主要由众多创新小型公司推动，这些公司为寻求收购以加强其微生物组研究的主要相关人员提供了巨大的成长潜力。其目标是发现针对各种健康问题（包括肥胖症、肝病、糖尿病和代谢紊乱）的新药和药物标靶。主要企业正积极寻求策略伙伴关係和联盟，尤其旨在透过强大的研发倡议来拓展产品系列，从而充分把握不断增长的微生物组领域的潜力。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 监管环境
• 案例研究

全球微生物组市场规模（按产品和复合年增长率划分）（2026-2033 年）

• 益生菌
• 食物
• 益生元
• 特殊医学食品
• 其他的

全球微生物组市场规模（按应用及复合年增长率划分）（2026-2033 年）

• 治疗药物
• 诊断

全球微生物组市场规模及复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

主要企业简介

• Seres Therapeutics（USA）
• Ferring Pharmaceuticals（Switzerland）
• BiomeBank（Australia）
• Seed Health（USA）
• International Flavors & Fragrances Inc.（USA）
• Pendulum Therapeutics（USA）
• BioHM Health Inc.（USA）
• Actial Farmaceutica SRL（Italy）
• Optibiotix Health plc（UK）
• Resbiotic（USA）
• Infinant Health Inc.（USA）
• Biogaia AB（Sweden）
• Exegi Pharma LLC（USA）
• Vedanta Biosciences Inc.（USA）
• Enterome（France）
• Yakult（Japan）
• DuPont（USA）
• Metabiomics Corporation（USA）
• ViThera Pharmaceuticals（USA）
• Second Genome（USA）

结论与建议

Global Microbiome Market size was valued at USD 1072.25 Million in 2024 and is poised to grow from USD 1262.04 Million in 2025 to USD 4648.19 Million by 2033, growing at a CAGR of 17.7% during the forecast period (2026-2033).

The global microbiome market is experiencing significant growth driven by a surge in strategic partnerships aimed at advancing research and development in microbiome therapies. This collaborative approach enhances product innovation and development, positioning the market for novel treatment solutions. The anticipated rollout of groundbreaking medications, alongside an expanding portfolio of microbiome-based therapies, further fuels market momentum. Additionally, the rising incidence of diseases that microbiome interventions can address contributes to heightened demand for these therapies. As awareness of the microbiome's critical role in health and disease continues to grow, the potential for impactful therapies is creating a dynamic and evolving landscape in the healthcare sector, offering numerous opportunities for stakeholders.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Microbiome market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Microbiome Market Segments Analysis

Global Microbiome Market is segmented by Product, Application and region. Based on Product, the market is segmented into Probiotics, Foods, Prebiotics, Medical food and Others. Based on Application, the market is segmented into Therapeutics and Diagnostics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Microbiome Market

The global microbiome market is driven by the crucial role human gut microbiomes play in enhancing the effectiveness of medicinal treatments. Research indicates that maintaining a balanced community of microorganisms within the body can aid in the management of various health conditions. This connection between microbial flora and specific diseases presents opportunities for innovation in drug development and vaccine creation. Additionally, the abundant enzymes produced by these microbes offer potential for diverse therapeutic applications, revealing new pathways for the discovery of novel treatments and highlighting the importance of microbiomes in advancing healthcare solutions.

Restraints in the Global Microbiome Market

The Global Microbiome market faces significant restraints due to regulatory challenges surrounding probiotics. Although FDA approval has not been granted for probiotics as live biotherapeutic products, they can still be legally marketed as part of food and dietary supplements. This regulatory framework limits their promotion, preventing these products from being marketed with claims of curing, mitigating, treating, or preventing diseases. Consequently, this restriction can hinder market growth and consumer perception, as companies may struggle to communicate the potential benefits of probiotics effectively while adhering to strict advertising guidelines. The lack of regulatory clarity can ultimately affect investment and innovation within the microbiome sector.

Market Trends of the Global Microbiome Market

The Global Microbiome market is witnessing a notable trend marked by an uptick in collaborations between public and private organizations. This surge is fueled by numerous innovative smaller enterprises that present high-growth prospects for larger stakeholders seeking acquisitions to enhance their research into microbiomes. The objective is to uncover novel drugs and drug targets for a diverse array of health conditions, including obesity, liver disorders, diabetes, and metabolic issues. Key players are increasingly engaging in strategic partnerships and alliances, particularly aimed at expanding their product portfolios through robust R&D initiatives, thereby positioning themselves to capitalize on the growing potential of the microbiome landscape.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies

Global Microbiome Market Size by Product & CAGR (2026-2033)

• Market Overview
• Probiotics
• Foods
• Prebiotics
• Medical food
• Others

Global Microbiome Market Size by Application & CAGR (2026-2033)

• Market Overview
• Therapeutics
• Diagnostics

Global Microbiome Market Size & CAGR (2026-2033)

• North America (Product, Application)
  • US
  • Canada
• Europe (Product, Application)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Application)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Application)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Application)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Seres Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ferring Pharmaceuticals (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BiomeBank (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Seed Health (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• International Flavors & Fragrances Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pendulum Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioHM Health Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Actial Farmaceutica SRL (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Optibiotix Health plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Resbiotic (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Infinant Health Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogaia AB (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exegi Pharma LLC (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vedanta Biosciences Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Enterome (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Yakult (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DuPont (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Metabiomics Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ViThera Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Second Genome (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations